ADPS™
EML4-ALK Gene Fusion Detection Kit
Enhancing EML4-ALK Research Outcomes with Ultra-Sensitivity
Enhancing EML4-ALK Research Outcomes with Ultra-Sensitivity
The EML4-ALK fusion gene is frequently found in non-small cell lung cancer (NSCLC). It is known to activate the downstream signaling pathway of receptor tyrosine kinase, leading to cancer development. The presence of the EML4-ALK fusion gene has been reported to correlate with the efficacy of ALK-targeted therapies.
The ADPS™ EML4-ALK Gene Fusion Detection Kit accurately detects 10 types of EML4-ALK fusion genes, representing approximately 97% of EML4-ALK cases found in NSCLC, at 50 copies per reaction. This is a one-step RT-qPCR test designed to test RNA extracted from both tissue and plasma samples with a single kit.
This product is for research use only (RUO) and not intended for use in diagnostic procedures.
| Catalog No. | (RUO) R8014APA |
|---|---|
| Coverage | 97% of EML4-ALK variants in NSCLC (10 fusions) |
| Fusion partner by NCCN guideline |
EML4-ALK |
| Assay type | One-step RT-qPCR |
| Sample type | DNA extracted from FFPE, frozen, and fresh cancer tissue or liquid biopsy |
| Master Mixture (MMX) |
1MMX |
| Internal Control | GusB |
| Detection Sensitivity | 50 copies/reaction |
| Detection Specificity | ≥ 99% |
| Precision (% CV) | ≤ 5% (CV, coefficient of variation) |
| Storage | -20±5℃ |
| Stability | 10 months |
| Freeze/Thaw stability | 5 times |
| Compatible Instruments | AB 7500 Fast, CFX96, QuantStudio 5 |
ADPS™ Oncogene Mutation Test